abrdn plc acquired a new stake in TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) during the 4th quarter, Holdings Channel.com reports. The firm acquired 200,000 shares of the company’s stock, valued at approximately $1,166,000. Separately, Pale Fire Capital SE bought a new stake in shares of TScan Therapeutics during the 3rd quarter valued at $42,000. […]
Wedbush restated their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) in a research report released on Tuesday, Benzinga reports. They currently have a $10.00 price target on the stock. Separately, HC Wainwright reissued a buy rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research note […]
Wedbush restated their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) in a research note published on Wednesday morning, RTT News reports. The firm currently has a $10.00 target price on the stock. Wedbush also issued estimates for TScan Therapeutics’ Q1 2024 earnings at ($0.27) EPS, Q2 2024 earnings at ($0.23) EPS, […]